SOURCE: Enterey, Inc. Life Sciences Consulting
IRVINE, CA--(Marketwire - Jul 31, 2012) - On the eve of its 10-year anniversary, Enterey Life Sciences Consulting reflects on a decade in the life sciences industry.
Born in 2002, Enterey Life Sciences Consulting was the brainchild of CEO Mike Ferletic, who had worked in traditional large consulting firms but had the vision of creating a more flexible business model with solutions customized to clients' needs. Ten years later, Enterey boasts top-tier clients in biotech and big pharma, realizing their goal of a more personalized approach to life sciences consulting.
But what was the climate in the life sciences, both inside and outside Enterey's doors, over these past 10 years?
In 2002, innovation was in the air: the Braille Glove was designed to translate sign language into text, and Ortho McNeil's OrthoEvra birth control patch streamlining birth control. That same year, researchers successfully sequenced the DNA of rice, making it the first crop to have its genome decoded.
A year later, in 2003, the sequencing of the human genome was completed, allowing for genetically based treatments for disease and paving the way for personalized medicine. Eli Lilly's Cialis hit the market, giving Pfizer's Viagra (launched in 1998) some tough competition. And, the Infrared Fever Screening System was deployed by the Singapore Defense and Science and Technology Agency to scan the public for high fever after the SARS outbreak that shook 29 countries.
The year 2004 held many "firsts": Enterey launched its first website, acquired its first international client, and secured its first Prime Contract. It was also the year that the first anti-angiogenic drug -- Genentech's Avastin -- was approved by the FDA to treat cancer.
By 2005, Shire's Adderall was showing positive results in adults with ADHD. A year later, Enterey had matured, earning it first $1M in sales. The Medicare Prescription Drug, Improvement, and Modernization Act took effect, making it the first comprehensive drug benefit offered by Medicare. The NIH sponsored the 10-year, 10,000-patient TAYLORx clinical trial of the Oncotype Dx, a cancer assay that revolutionized the breast cancer treatment landscape.
In '07, Biogen Idec sold the U.S. rights for Zevalin, a treatment for non-Hodgkin's lymphoma, to Cell Therapeutics. (Zevalin is now owned by Spectrum Pharmaceuticals.) Two years later, sales continued to shape the industry: Pfizer bought Wyeth for $68B; Roche bought Genentech for $46.8B; and Merck bought Schering-Plough for $41B.
Also in 2009, blockbuster drugs Zoloft (Pfizer) and Zocor (Merck) came off patent. GSK and Pfizer partnered to form ViiV Healthcare to join forces in the fight against HIV. And, the Boston Retinal Implant Project released a retinal implant for patients with age-related macular degeneration.
For Enterey, the company had formed a solid corporate identity by 2009 and redesigned its logo to evoke empowerment. Last year, Enterey published its first blog, giving clients useful information on industry topics. And in 2012, offices in Illinois and Ohio were opened, allowing Enterey to venture into the Midwestern market.
What's next for the decade-old company? More diversification, more clients, and more services for our existing clients, followed by another ten successful years.
Enterey Life Sciences Consulting provides life sciences consulting expertise in both process- and systems-related projects for biotech, medical device, and pharmaceutical clients. Enterey provides solutions ranging from strategic planning to business-integration, and has a proven track record of success supporting both clinical and commercial facility start-ups.
Contact Enterey at (800) 691-2349 or visit us at www.enterey.com for more information.